Top ▲
Target has curated data in GtoImmuPdb
Target id: 1759
Nomenclature: TLR9
Family: Toll-like receptor family
Annotation status:
Awaiting annotation
» Email us
Gene and Protein Information ![]() |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 1032 | 3p21.2 | TLR9 | toll like receptor 9 | |
| Mouse | 1 | 1032 | 9 F1 | Tlr9 | toll-like receptor 9 | |
| Rat | - | - | 8 | Tlr9 | toll-like receptor 9 | |
Previous and Unofficial Names ![]() |
| CD289 | toll-like receptor 9 |
Database Links ![]() |
|
| Alphafold | Q9NR96 (Hs), Q9EQU3 (Mm) |
| CATH/Gene3D | 3.80.10.10, 3.40.50.10140 |
| ChEMBL Target | CHEMBL5804 (Hs), CHEMBL6128 (Mm) |
| DrugBank Target | Q9NR96 (Hs) |
| Ensembl Gene | ENSG00000239732 (Hs), ENSMUSG00000045322 (Mm), ENSRNOG00000048161 (Rn) |
| Entrez Gene | 54106 (Hs), 81897 (Mm), 338457 (Rn) |
| Human Protein Atlas | ENSG00000239732 (Hs) |
| KEGG Gene | hsa:54106 (Hs), mmu:81897 (Mm), rno:338457 (Rn) |
| OMIM | 605474 (Hs) |
| Pharos | Q9NR96 (Hs) |
| UniProtKB | Q9NR96 (Hs), Q9EQU3 (Mm) |
| Wikipedia | TLR9 (Hs) |
Download all structure-activity data for this target as a CSV file
| Agonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antagonists | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| TLR9 is an endosomal receptor detecting viral and bacterial CpG DNA and genomic DNA from some protozoan species [7]. Activated TLR9 receptors expressed by B cells and plasmacytoid dendritic cells, stimulate human B-cell proliferation, enhance antigen-specific antibody production and induce IFN-α production, IL-10 secretion and natural killer cell activity. |
| Immuno Process Associations | |||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
| General Comments |
|
TLR9 is an intracellular detector for pathogen-derived nucleic acids, in particular CpG dinucleotides. Trafficking of endosomal TLR9 is tightly controlled to prevent inappropriate activation [2]. The potential role of TLR9 in immuno-oncology is reviewed in [1]. |
1. Adams JL, Smothers J, Srinivasan R, Hoos A. (2015) Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov, 14 (9): 603-22. [PMID:26228631]
2. Babdor J, Descamps D, Adiko AC, Tohmé M, Maschalidi S, Evnouchidou I, Vasconcellos LR, De Luca M, Mauvais FX, Garfa-Traore M et al.. (2017) IRAP+ endosomes restrict TLR9 activation and signaling. Nat Immunol, 18 (5): 509-518. [PMID:28319098]
3. Dyckman AJ, Dodd DS, Mussari CP, Pasunoori L, Kumar SR. (2019) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds. Patent number: US10478424B2. Assignee: Syngene International Ltd, Bristol Myers Squibb Co. Priority date: 23/07/2018. Publication date: 19/11/2019.
4. Karapetyan L, Luke JJ, Davar D. (2020) Toll-Like Receptor 9 Agonists in Cancer. Onco Targets Ther, 13: 10039-10060. [PMID:33116588]
5. Lamphier M, Zheng W, Latz E, Spyvee M, Hansen H, Rose J, Genest M, Yang H, Shaffer C, Zhao Y et al.. (2014) Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol, 85 (3): 429-40. [PMID:24342772]
6. Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S et al.. (2020) The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. J Crohns Colitis, 14 (4): 508-524. [PMID:31630153]
7. Uematsu S, Akira S. (2008) Toll-Like receptors (TLRs) and their ligands. Handb Exp Pharmacol, (183): 1-20. [PMID:18071652]
8. Wang D, Jiang W, Zhu F, Mao X, Agrawal S. (2018) Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. Int J Oncol, 53 (3): 1193-1203. [PMID:29956749]
9. Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C. (2016) Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A, 113 (46): E7240-E7249. [PMID:27799536]
10. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit Rev Oncol Hematol, 94 (1): 31-44. [PMID:25577571]
11. Zhang Z, Dey F, Liu H, Rudolph MG, Liu Y, Wang X, Zhang W, Zhang Z, Kou B, Zou G et al.. (2026) Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities. J Med Chem, [Epub ahead of print]. [PMID:42484069]
12. (2006) CpG 7909: PF 3512676, PF-3512676. Drugs R D, 7 (5): 312-6. [PMID:16922592]